The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population

被引:18
|
作者
Seo, Ji Yeon [1 ]
Cho, Eun Ju [2 ]
Kim, Min Joo [3 ]
Kwak, Min-Sun [1 ]
Yang, Jong In [1 ]
Chung, Su Jin [1 ]
Yim, Jeong Yoon [1 ]
Yoon, Ji Won [3 ]
Chung, Goh Eun [1 ]
机构
[1] Seoul Natl Univ Hosp, Internal Med & Healthcare Res Inst, Dept Gastroenterol & Hepatol, Healthcare Syst Gangnam Ctr, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Internal Med & Liver Res Inst, Dept Gastroenterol & Hepatol, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Internal Med & Healthcare Res Inst, Dept Endocrinol, Healthcare Syst Gangnam Ctr, Seoul, South Korea
关键词
fibrosis; hepatic steatosis; low muscle mass; metabolic dysfunction; CONTROLLED ATTENUATION PARAMETER; INSULIN-RESISTANCE; HEPATIC STEATOSIS; SARCOPENIA; FIBROSIS; OBESITY;
D O I
10.1002/jcsm.13099
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background Metabolic (dysfunction)-associated fatty liver disease (MAFLD) emphasizes the metabolic dysfunction in nonalcoholic fatty liver disease (NAFLD). Although the relationship between low muscle mass and NAFLD has been suggested, the effect of MAFLD on low muscle mass is yet to be investigated. In this study, we examined the relationship between MAFLD and low muscle mass in an asymptomatic Korean population. Methods Examinees who underwent FibroScan (R) and bioelectrical impedance analyses on the same day during the period of June 2017 to December 2019 were included. Hepatic steatosis was diagnosed using controlled attenuation parameter (CAP) with two cut-off values of 248 and 294 dB/m. Low muscle mass was defined based on appendicular skeletal muscle mass/body weight (wt) or body mass index (BMI) ratios of two standard deviations below the sex-specific mean for healthy young adults. Subjects were divided into four subgroups: diabetic MAFLD (presence of diabetes mellitus [DM]), metabolic dysfunction (MD) MAFLD (=2 metabolic abnormalities without DM), overweight MAFLD (overweight/obese without DM and <2 metabolic abnormalities) and no MAFLD. Results Among all of the 6414 subjects (mean 53.9 years of age; 85.4% male), the prevalence of MAFLD was 49.9% and 22.7% for CAP cut-off values of 248 and 294 dB/m, respectively. In the multivariate analysis, MAFLD was associated with an increased risk of both low muscle mass_wt (odds ratio [OR] 1.80, 95% confidence interval [CI] 1.38-2.35, P < 0.001) and low muscle mass_BMI (OR 1.31, 95% CI 1.01-1.70, P = 0.042). The risk of low muscle mass_wt and low muscle mass_BMI increased the most in the diabetic MAFLD subgroup compared with the no-MAFLD group (OR 2.11, 95% CI 1.51-2.96, P < 0.001 and OR 1.51, 95% CI 1.08-2.13, P = 0.017). There was an increased risk of low muscle mass_wt in the MD MAFLD subgroup (OR 1.73, 95% CI 1.31-2.28, P < 0.001). Comparable results were observed when the CAP cut-off value of 294 dB/m was applied. Conclusions The presence of MAFLD is significantly associated with increased risk of low muscle mass with varying risks according to the MAFLD subgroups. Clinicians should be aware of the differentiated risk of low muscle mass across the subgroups of MAFLD.
引用
收藏
页码:2953 / 2960
页数:8
相关论文
共 50 条
  • [1] Association of low muscle strength with metabolic dysfunction-associated fatty liver disease: A nationwide study
    Lee, Gyu Bae
    Huh, Youn
    Lee, Sang Hyun
    Han, Byoungduck
    Kim, Yang-Hyun
    Kim, Do-Hoon
    Kim, Seon Mee
    Choi, Youn Seon
    Cho, Kyung Hwan
    Nam, Ga Eun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (45) : 5962 - 5973
  • [2] The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
    Barrera, Francisco
    Uribe, Javier
    Olvares, Nixa
    Huerta, Paula
    Cabrera, Daniel
    Romero-Gomez, Manuel
    ANNALS OF HEPATOLOGY, 2024, 29 (04)
  • [3] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [4] Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
    Malik, Adnan
    Javaid, Sadia
    Malik, Muhammad Imran
    Qureshi, Shahbaz
    ANNALS OF HEPATOLOGY, 2024, 29 (06)
  • [5] Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
    Lim, Soo
    Kim, Jin-Wook
    Targher, Giovanni
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2021, 32 (07) : 500 - 514
  • [6] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi, Yiwen
    Fan, Jiangao
    CHINESE MEDICAL JOURNAL, 2022, 135 (09) : 1009 - 1018
  • [7] Non-invasive assessment of metabolic dysfunction-associated fatty liver disease
    Chandra Kumar, C. Vikneshwaran
    Skantha, Ruben
    Chan, Wah-Kheong
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
  • [8] Diabetes and metabolic dysfunction-associated fatty liver disease
    Davis, Timothy M. E.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 123
  • [9] Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population
    Lee, Guan Huei
    Phyo, Wah Wah
    Loo, Wai Mun
    Kwok, Raymond
    Ahmed, Taufique
    Shabbir, Asim
    So, Jimmy
    Koh, Calvin Jianyi
    Hartono, Juanda Leo
    Muthiah, Mark
    Lim, Kieron
    Tan, Poh Seng
    Lee, Yin Mei
    Lim, Seng Gee
    Dan, Yock Young
    WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (12) : 1228 - 1238
  • [10] Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children
    Rupasinghe, Kushila
    Hind, Jonathan
    Hegarty, Robert
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 77 (05) : 583 - 591